Clinical trial
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies…
NCT00148421 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00148421 |
|---|---|
| Title | Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy. |
| Official title | A Study of Darbepoetin Alfa Administered Once Every 2 Weeks (Q2W) Compared With Epoetin Alfa Administered Once Every Week (QW) for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy. |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anemia |
| Intervention type | Drug |
| Interventions | Darbepoetin alfa and Epoetin alfa |
| First posted | Sep 8, 2005 |
| Last update posted | May 15, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: